Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ BJ′s Wholesale Club Holdings, Inc. Announces Second Quarter Fiscal 2025 Results (Business Wire) +++ BJ'S WHOLESALE Aktie -3,83%

PACIFIC BIOSCIENCES Aktie

 >Aktienkurs 
1.0868 EUR    -0.3%    (Tradegate)
Ask: 1.1286 EUR / 4500 Stück
Bid: 1.0868 EUR / 4600 Stück
Tagesumsatz: 1300 Stück
Realtime Kurs von 8 bis 22 Uhr!
Aktie über LYNX handeln
>Performance
1 Woche: -0,6%
1 Monat: -14,4%
3 Monate: +23,3%
6 Monate: -27,0%
1 Jahr: -20,4%
laufendes Jahr: -38,3%
>PACIFIC BIOSCIENCES Aktie
Name:  PACIFIC BIOSCIENCES
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US69404D1081 / A1C3EQ
Symbol/ Ticker:  P09 (Frankfurt) / PACB (NASDAQ)
Kürzel:  FRA:P09, ETR:P09, P09:GR, NASDAQ:PACB
Index:  -
Webseite:  http://www.pacificbioscie..
Profil:  Pacific Biosciences of California, Inc. is a biote..
>Volltext..
Marktkapitalisierung:  335.11 Mio. EUR
Unternehmenswert:  661.02 Mio. EUR
Umsatz:  133.97 Mio. EUR
EBITDA:  -141.57 Mio. EUR
Nettogewinn:  -450.69 Mio. EUR
Gewinn je Aktie:  -1.53 EUR
Schulden:  600.06 Mio. EUR
Liquide Mittel:  47.29 Mio. EUR
Operativer Cashflow:  -128.34 Mio. EUR
Bargeldquote:  5.27
Umsatzwachstum:  -24.84%
Gewinnwachstum:  -19.26%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  1 Insider verkaufte innerhalb der letzten 30 Tage Aktien im Wert von 35.182 USD.
Suchwörter:  PACIFIC BIOSCIENCES, PACIFIC BIOSCIENCE
Letzte Datenerhebung:  22.08.25
>Kennzahlen
Aktien/ Unternehmen:
Aktien: 300.37 Mio. St.
Frei handelbar: 88.03%
Rückkaufquote: -0.71%
Mitarbeiter: 575
Umsatz/Mitarb.: 0.23 Mio. EUR
Analysten:
Analystenrating: Buy
Kursziel: 57.45%
Bewertung:
KGV: -
KGV lG: -
KUV: 2.5
KBV: 6.28
PEG-Ratio: -0.01
EV/EBITDA: -
Rentabilität:
Bruttomarge: -215.73%
Gewinnmarge: -336.4%
Operative Marge: -364.72%
Managementeffizenz:
Gesamtkaprendite: -44.98%
Eigenkaprendite: -189.52%
>Peer Group

Es sind 601 Aktien bekannt.
 
21.08.25 - 02:01
Insiderhandel: Vorstand verkauft Aktien von Pacific Biosciences of California im Wert von 35182 USD (Insiderkauf)
 
Van Oene Mark - Vorstand - Tag der Transaktion: 2025-08-18...
08.08.25 - 03:15
Pacific Biosciences (PACB) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
 
The headline numbers for Pacific Biosciences (PACB) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals....
08.08.25 - 02:30
Pacific Biosciences of California (PACB) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
 
Pacific Biosciences (PACB) delivered earnings and revenue surprises of +27.78% and +9.06%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?...
07.08.25 - 22:12
Pacific Biosciences of California Non-GAAP EPS of -$0.13 beats by $0.04, revenue of $39.8M beats by $3.33M (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
30.07.25 - 01:45
Pacific Biosciences of California (PACB) Suffers a Larger Drop Than the General Market: Key Insights (Zacks)
 
Pacific Biosciences of California (PACB) reached $1.54 at the closing of the latest trading day, reflecting a -6.1% change compared to its last close....
18.07.25 - 01:45
Pacific Biosciences of California (PACB) Stock Sinks As Market Gains: What You Should Know (Zacks)
 
Pacific Biosciences of California (PACB) reached $1.39 at the closing of the latest trading day, reflecting a -6.71% change compared to its last close....
11.07.25 - 01:45
Pacific Biosciences of California (PACB) Beats Stock Market Upswing: What Investors Need to Know (Zacks)
 
The latest trading day saw Pacific Biosciences of California (PACB) settling at $1.5, representing a +1.35% change from its previous close....
08.07.25 - 19:45
Pacific Biosciences (PACB) Upgraded to Strong Buy: Here′s What You Should Know (Zacks)
 
Pacific Biosciences (PACB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy)....
01.07.25 - 01:45
Pacific Biosciences of California (PACB) Stock Sinks As Market Gains: What You Should Know (Zacks)
 
The latest trading day saw Pacific Biosciences of California (PACB) settling at $1.24, representing a -3.88% change from its previous close....
13.06.25 - 01:45
Pacific Biosciences of California (PACB) Outperforms Broader Market: What You Need to Know (Zacks)
 
Pacific Biosciences of California (PACB) closed at $1.18 in the latest trading session, marking a +1.72% move from the prior day....
29.05.25 - 19:45
All You Need to Know About Pacific Biosciences (PACB) Rating Upgrade to Buy (Zacks)
 
Pacific Biosciences (PACB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy)....
22.05.25 - 02:01
Insiderhandel: Vorstand verkauft Aktien von Pacific Biosciences of California im Wert von 5200 USD (Insiderkauf)
 
Farmer, Michele - Vorstand - Tag der Transaktion: 2025-05-19...
15.05.25 - 16:33
Where Pacific Biosciences Stands With Analysts (Benzinga)
 
Latest Ratings for PACB DateFirmActionFromTo Feb 2022Canaccord GenuityMaintainsBuy Sep 2021Canaccord GenuityInitiates Coverage OnBuy Aug 2021Morgan StanleyMaintainsEqual-Weight View More Analyst Ratings for PACB View the Latest Analyst Ratings read more...
09.05.25 - 04:45
Pacific Biosciences (PACB) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
 
While the top- and bottom-line numbers for Pacific Biosciences (PACB) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values....
09.05.25 - 01:00
Pacific Biosciences of California (PACB) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
 
Pacific Biosciences (PACB) delivered earnings and revenue surprises of 21.05% and 6.15%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?...
30.04.25 - 01:45
Pacific Biosciences of California (PACB) Stock Falls Amid Market Uptick: What Investors Need to Know (Zacks)
 
In the latest trading session, Pacific Biosciences of California (PACB) closed at $1.11, marking a -1.77% move from the previous day....
24.04.25 - 01:45
Pacific Biosciences of California (PACB) Flat As Market Gains: What You Should Know (Zacks)
 
In the latest trading session, Pacific Biosciences of California (PACB) closed at $1.17, marking no change from the previous day....
09.04.25 - 16:01
PacBio Q1 Prel. Revenue Down, Says Met Expectations; To Cut Jobs (AFX)
 
WASHINGTON (dpa-AFX) - Pacific Biosciences of California, Inc. (PACB) Wednesday reported preliminary revenue of $36.9 million for the first quarter, lower than $38.8 million in the previous year.T......
09.04.25 - 15:57
Pacific Biosciences of California jumps 9% after prelim Q1 results, guides FY (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Das nackte Kind, das zagt nicht; mit seinem Pfennig springt es fort und kennt recht gut den Sammelort - ich meine des Bäckers Laden. - Johann Wolfgang von Goethe
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!